An interventional study of cervical sensorimotor rehabilitation and conventional physiotherapy programme in Chronic Migraine, sponsored by Beni-Suef University. Enrolling by invitation at 1 site in Egypt. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Beni-Suef University · Not applicable, Interventional, and Treatment
Among 29 studies in Migraine Disorders with a site in Egypt — 17 open to participants now, 18 under way, 2 of them phase 3. Migraine Disorders · Egypt.
Among the 29 studies in Migraine Disorders with a site in Egypt, this one is the 13th largest by planned enrollment of the 23 interventional ones, is one of 4 that started in 2026, is one of 13 with no phase, reaches primary completion later than 15 of the 17 other live ones, and was the 27th registered.
1,657 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.
This study's planned enrollment of 80 is close to the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Browse Migraine Disorders studies →17 of the 29 studies in Migraine Disorders with a site in Egypt are open now, in 1 country. Each count lists the studies.
Of the 216 Migraine Disorders studies recruiting now, 65 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →29 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 4 started in 2026.
Median enrollment 90 across the 23 interventional studies, 103 across the 6 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
None of the 29 has an industry lead sponsor. The 10 most frequent:
Beni-Suef University is the lead sponsor of 349 studies on the registry; 125 are open to participants now.
Beni-Suef University has 4 studies filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
3 of the studies in Migraine Disorders with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07849283Sohag UniversityEfficacy of Cognitive Behavioral Therapy at Vestibular Migraine | 2027-02 |
| NCT07762690Beni-Suef UniversityMechanism-Based Cervical Rehabilitation for Chronic Migraine | 2027-02-25 |
| NCT07769255Beni-Suef UniversityEffect of Nebulized Dexmedetomidine on Central Sensitization and Chronification in Migraine | 2027-03-01 |
Among the 29 studies in Migraine Disorders with a site in Egypt, from their registry updates:
To investigate the effectiveness of mechanism-based cervical sensorimotor rehabilitation on cervical muscle activation, cervical proprioception, and migraine burden.
Chronic migraine is a disabling neurological disorder characterised by headache occurring on at least 15 days per month for more than three months, with migraine features on at least eight days per month according to the International Classification of Headache Disorders (ICHD-3). In addition to headache symptoms, individuals with chronic migraine frequently exhibit cervical musculoskeletal impairments, including reduced cervical range of motion, impaired cervical proprioception, altered neuromuscular control, and increased activity of superficial cervical muscles. These impairments are thought to be associated with altered sensorimotor integration and dysfunction of the trigeminocervical complex, potentially contributing to headache persistence and disability.
Although several studies have reported beneficial effects of cervical rehabilitation in patients with migraine, the underlying neuromuscular mechanisms remain insufficiently understood. In particular, few randomized controlled trials have simultaneously investigated changes in cervical muscle activation, cervical joint position error, and migraine-related outcomes following a structured cervical sensorimotor rehabilitation programme. Understanding these mechanisms may improve clinical decision-making and facilitate the development of targeted rehabilitation strategies. This study is a prospective, assessor-blinded, parallel-group randomized controlled trial designed to investigate the effectiveness of a mechanism-based cervical sensorimotor rehabilitation programme in patients with chronic migraine.
A total of 80 participants diagnosed with chronic migraine according to the International Classification of Headache Disorders, Third Edition (ICHD-3) will be recruited from the outpatient clinics of the Faculty of Physical Therapy, Beni-Suef University. Participants will be randomly allocated in a 1:1 ratio to either an experimental group or a control group using a computer-generated randomization sequence with concealed allocation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
History of migraine for at least 12 months prior to enrolment. Experiencing chronic migraine during the previous three months, confirmed through clinical history and/or headache diary.
Presence of cervical sensorimotor impairment, demonstrated by at least one of the following:
Increased cervical joint position error. Reduced cervical range of motion. Impaired cervical motor control. Neck pain or cervical dysfunction associated with migraine.
Exclusion Criteria:
Previous cervical spine surgery, fracture, or significant cervical trauma. Cervical radiculopathy, myelopathy, or severe cervical spine pathology. Neurological disorders other than migraine (e.g., stroke, multiple sclerosis, Parkinson's disease).
Vestibular disorders affecting balance or proprioception. Inflammatory or systemic musculoskeletal diseases (e.g., rheumatoid arthritis, ankylosing spondylitis).
Pregnancy or breastfeeding. Physiotherapy, chiropractic treatment, acupuncture, or cervical rehabilitation within the previous 3 months.
Botulinum toxin injections or cervical pain interventions within the previous 3-4 months.
Changes in migraine preventive medication within the previous 4 weeks. Skin conditions preventing surface EMG electrode placement. Inability to comply with the study protocol or provide .
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
he experimental group will receive an eight-week mechanism-based cervical sensorimotor rehabilitation programme consisting of deep cervical flexor training, cervical motor control exercises, laser-guided cervical joint position error retraining, eye-head coordination exercises, scapular neuromuscular stabilization exercises, and a structured home exercise programme. Treatment will be delivered three sessions per week, with each session lasting approximately 40 minutes.
Other: cervical sensorimotor rehabilitation · Other: conventional physiotherapy programme
The control group will receive conventional physiotherapy, including cervical range of motion exercises, stretching exercises, postural education, and a home exercise programme, with the same treatment frequency and duration as the experimental group.
Other: conventional physiotherapy programme
he experimental group will receive an eight-week mechanism-based cervical sensorimotor rehabilitation programme consisting of deep cervical flexor training, cervical motor control exercises, laser-guided cervical joint position error retraining, eye-head coordination exercises, scapular neuromuscular stabilization exercises, and a structured home exercise programme. Treatment will be delivered three sessions per week, with each session lasting approximately 40 minutes.
Describe the conventional physiotherapy programme in the same level of detail as the experimental intervention, including exercise dosage, repetitions, duration, progression, and home programme.
cervical joint position error
Cervical Joint Position Error (JPE) will be assessed to evaluate cervical proprioception using the Head Repositioning Accuracy Test. A lightweight laser pointer will be securely attached to the participant's head using an adjustable headband. Participants will be seated comfortably at a distance of 90 cm from a target grid mounted on a wall at eye level. At the beginning of each trial, participants will be instructed to identify and memorise their neutral head position while visually focusing on the centre of the target. They will then close their eyes and actively move their head to the end range of the required movement (flexion, extension, right rotation, left rotation, right lateral flexion, or left lateral flexion, depending on the testing protocol) before attempting to return to the original neutral position without visual feedback.The distance between the original target position and the repositioned laser point will be recorded and converted into angular error (degrees). Thre
Time frame: after the 8-week intervention, and at the 3-month follow-up
Headache Impact Test (HIT-6)
The Headache Impact Test (HIT-6) will be used to assess the impact of headaches on participants' daily functioning and health-related quality of life. The HIT-6 is a validated, self-administered questionnaire consisting of six items that evaluate headache-related limitations in pain severity, social functioning, role functioning, vitality, cognitive functioning, and psychological distress over the previous four weeks. Each item is scored using a five-point Likert scale with the following response options: Never = 6 points Rarely = 8 points Sometimes = 10 points Very Often = 11 points Always = 13 points The total score ranges from 36 to 78 points, with higher scores indicating a greater negative impact of headaches on daily life.
Time frame: after the 8-week intervention (Week 8), and at the 3-month follow-up
Surface electromyographic (sEMG)
Surface electromyography (sEMG) will be used to assess the neuromuscular activity of the bilateral sternocleidomastoid (SCM) and upper trapezius (UT) muscles. Disposable Ag/AgCl bipolar surface electrodes will be placed over each muscle according to the Surface Electromyography for the Non-Invasive Assessment of Muscles (SENIAM) recommendations following skin preparation (shaving if necessary, light abrasion, and cleaning with alcohol). The primary sEMG variables will include the root mean square (RMS) amplitude (µV) of the muscle activation during each task. If maximal voluntary isometric contraction (MVIC) testing is feasible, RMS values will be normalized and expressed as a percentage of MVIC (%MVIC) to facilitate comparisons between participants. If MVIC normalization is not performed, RMS values will be reported in microvolts (µV). The mean value of the three trials will be used for statistical analysis. Surface EMG measurements will be obtained at baseline (Week 0), immediately
Time frame: baseline of 8-week intervention, and at the 3-month follow-up
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Feb 2027, 4 months later.
Of 309 non-industry interventional studies with no phase under Migraine Disorders, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 4 months is below that.
Counting every sponsor, half of 358 studies reached it within 15 months; a quarter within 7 and three quarters within 34.
Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, on Oct 13, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.